|
WO2010037001A2
(en)
|
2008-09-26 |
2010-04-01 |
Immune Disease Institute, Inc. |
Selective oxidation of 5-methylcytosine by tet-family proteins
|
|
EP3425065B1
(en)
|
2011-12-13 |
2021-04-21 |
Oslo Universitetssykehus HF |
Methods and kits for detection of methylation status
|
|
ES2786984T3
(es)
|
2012-11-30 |
2020-10-14 |
Cambridge Epigenetix Ltd |
Agente oxidante para nucleótidos modificados
|
|
SG11201505858VA
(en)
|
2013-01-28 |
2015-09-29 |
St Jude Childrens Res Hospital |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
KR20160004299A
(ko)
|
2013-04-09 |
2016-01-12 |
릭스트 바이오테크놀로지, 인코포레이티드 |
옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
BR112017000939A2
(pt)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico de cll-1
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
AU2015357535B2
(en)
|
2014-12-05 |
2020-05-14 |
Eureka Therapeutics, Inc. |
Antibodies targeting G-protein coupled receptor and methods of use
|
|
RU2751362C2
(ru)
|
2014-12-29 |
2021-07-13 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017059245A2
(en)
|
2015-09-30 |
2017-04-06 |
Trustees Of Boston University |
Deadman and passcode microbial kill switches
|
|
GB201519340D0
(en)
*
|
2015-11-02 |
2015-12-16 |
Cambridge Entpr Ltd |
Methods of T-lymphocyte expansion
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US10041044B2
(en)
|
2016-07-29 |
2018-08-07 |
Trustees Of Boston University |
Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
|
|
US20190119636A1
(en)
|
2017-10-23 |
2019-04-25 |
Poseida Therapeutics, Inc. |
Modified stem cell memory t cells, methods of making and methods of using same
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
AU2017370731B2
(en)
|
2016-12-08 |
2022-06-02 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for modulation of immune response
|
|
WO2018132427A1
(en)
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Targeted t cells with cytotoxicity toward immunosuppressive cells
|
|
WO2018132518A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
RU2019133286A
(ru)
*
|
2017-03-22 |
2021-04-22 |
Новартис Аг |
Биомаркеры и средства терапии на основе т-клеток с car с повышенной эффективностью
|
|
KR20190130608A
(ko)
*
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
EP4759318A2
(en)
*
|
2017-04-14 |
2026-06-17 |
The General Hospital Corporation |
Chimeric antigen receptor t cells targeting the tumor microenvironment
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
WO2018200582A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Chimeric antibody/t-cell receptor constructs and uses thereof
|
|
EP3624834A1
(en)
*
|
2017-05-17 |
2020-03-25 |
Thunder Biotech Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
CN107177632B
(zh)
*
|
2017-05-27 |
2020-02-07 |
上海优卡迪生物医药科技有限公司 |
一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用
|
|
IL327498A
(en)
*
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
CN107557339A
(zh)
*
|
2017-09-19 |
2018-01-09 |
深圳市北科生物科技有限公司 |
特异性识别plac1的t细胞及其与细胞因子的联合的应用
|
|
CN107630005A
(zh)
*
|
2017-09-19 |
2018-01-26 |
深圳市北科生物科技有限公司 |
表达plac1特异性tcr的t细胞及其应用
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US12698499B2
(en)
|
2017-10-27 |
2026-08-04 |
The Trustees Of The University Of Pennsylvania |
Identifying epigenetic and transcriptional targets to prevent and reverse T cell exhaustion
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
CN107893055B
(zh)
*
|
2017-11-03 |
2020-07-17 |
深圳市默赛尔生物医学科技发展有限公司 |
一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
JP7037667B2
(ja)
|
2017-12-20 |
2022-03-16 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
CN111867619A
(zh)
|
2018-01-03 |
2020-10-30 |
曲生物制品公司 |
过继性细胞治疗的先天寻靶
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
WO2019144707A1
(zh)
*
|
2018-01-26 |
2019-08-01 |
重庆精准生物技术有限公司 |
一种改良的铰链区及其在构建car骨架中的应用
|
|
TW201934575A
(zh)
|
2018-02-11 |
2019-09-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種分離的嵌合抗原受體以及包含其的修飾ｔ細胞及用途
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190284288A1
(en)
|
2018-03-19 |
2019-09-19 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
US20210047405A1
(en)
*
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019211799A1
(en)
|
2018-05-03 |
2019-11-07 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
|
|
JP6899975B2
(ja)
|
2018-05-14 |
2021-07-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｍｃｌ−１阻害剤
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
US20210379106A1
(en)
*
|
2018-06-14 |
2021-12-09 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes for enhancing car t cell function
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
CN109022435B
(zh)
*
|
2018-07-19 |
2022-05-06 |
佛山科学技术学院 |
一种条件性诱导小鼠精原细胞Tet3基因敲除细胞系及其构建方法
|
|
EP3826625A4
(en)
|
2018-07-23 |
2022-08-24 |
Magenta Therapeutics, Inc. |
USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY
|
|
AU2019315440B2
(en)
*
|
2018-07-30 |
2025-03-13 |
Angeles Therapeutics, Inc. |
Improving the efficacy and safety of adoptive cellular therapies
|
|
SI3844267T1
(sl)
|
2018-08-31 |
2025-10-30 |
Novartis Ag |
Postopki izdelave celic, ki izražajo receptorje himernega antigena
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US12698340B2
(en)
*
|
2018-10-01 |
2026-08-04 |
Adicet Therapeutics, Inc. |
Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors
|
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
US12624086B2
(en)
|
2018-10-31 |
2026-05-12 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
|
EP3873608A1
(en)
|
2018-10-31 |
2021-09-08 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
EP4371987B9
(en)
|
2018-10-31 |
2025-11-26 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
|
|
US12473345B2
(en)
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
AU2019387571A1
(en)
*
|
2018-11-30 |
2021-06-03 |
Celularity Inc. |
Placenta-derived allogeneic CAR-T cells and uses thereof
|
|
JP7646552B2
(ja)
|
2019-01-31 |
2025-03-17 |
ビーム セラピューティクス インク． |
低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
|
|
US12419913B2
(en)
|
2019-02-08 |
2025-09-23 |
Dna Twopointo, Inc. |
Modification of CAR-T cells
|
|
CA3129100A1
(en)
*
|
2019-02-08 |
2020-08-13 |
Biontech Cell & Gene Therapies Gmbh |
Treatment involving car-engineered t cells and cytokines
|
|
WO2020168135A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
WO2020165402A1
(en)
|
2019-02-14 |
2020-08-20 |
Westfälische Wilhelms-Universität Münster |
Gd2-upregulation by ezh2 inhibition in cancer therapy
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CN113574063B
(zh)
|
2019-03-07 |
2025-03-18 |
捷克共和国有机化学与生物化学研究所 |
3’3’-环二核苷酸及其前药
|
|
EP3942025A1
(en)
*
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
WO2020198734A1
(en)
*
|
2019-03-28 |
2020-10-01 |
The Penn State Research Foundation |
Methods, compositions relating to treatment of cancer
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020219843A1
(en)
*
|
2019-04-26 |
2020-10-29 |
The University Of North Carolina At Chapel Hill |
Chimeric antigen receptor constructs and their use in car-t cells
|
|
MX2021013218A
(es)
*
|
2019-05-01 |
2021-12-10 |
Pact Pharma Inc |
Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
|
|
WO2020237216A1
(en)
|
2019-05-22 |
2020-11-26 |
Jerome Canady Research Institute for Advanced Biological and Technological Sciences |
Method for cold atmospheric plasma exosome therapy
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
MX2022000852A
(es)
*
|
2019-07-24 |
2022-02-10 |
Eureka Therapeutics Inc |
Celulas que expresan receptores de antigenos quimericos y receptores estimulantes quimericos y usos de los mismos.
|
|
US20220288118A1
(en)
*
|
2019-07-31 |
2022-09-15 |
Forty Seven, Inc. |
Depletion regimes for engineered t-cell or nk-cell therapy
|
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
|
AU2020334317A1
(en)
|
2019-08-16 |
2022-04-07 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
|
PH12022550548A1
(en)
*
|
2019-09-06 |
2023-11-20 |
Crispr Therapeutics Ag |
Genetically engineered t cells having improved persistence in culture
|
|
US12551560B2
(en)
|
2019-09-09 |
2026-02-17 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
PH12022550835A1
(en)
|
2019-10-18 |
2023-07-03 |
Forty Seven Inc |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
NZ786589A
(en)
|
2019-10-31 |
2025-03-28 |
Forty Seven Llc |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
CN115362003B
(zh)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
二酰基甘油激酶调节化合物
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
JP2023516008A
(ja)
|
2020-02-27 |
2023-04-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
AU2021262547A1
(en)
|
2020-04-28 |
2022-11-10 |
Achilles Therapeutics Uk Limited |
T cell therapy
|
|
JP7564888B2
(ja)
|
2020-05-01 |
2024-10-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4168451A2
(en)
|
2020-06-22 |
2023-04-26 |
NGM Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
|
MX2023001142A
(es)
|
2020-07-30 |
2023-05-25 |
Cambridge Epigenetix Ltd |
Composiciones y metodos para analisis de acidos nucleicos.
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
WO2022094314A1
(en)
*
|
2020-10-30 |
2022-05-05 |
The University Of North Carolina At Chapel Hill |
Dual targeting chimeric antigen receptors
|
|
KR102605723B1
(ko)
*
|
2020-11-11 |
2023-11-24 |
한국과학기술원 |
키메라 항원 수용체를 위한 타깃 항원 발굴 방법 및 분석 장치
|
|
CN113045658B
(zh)
|
2020-12-11 |
2021-12-24 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
CN113234169B
(zh)
*
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
CN112662704A
(zh)
*
|
2020-12-31 |
2021-04-16 |
江苏集萃医学免疫技术研究所有限公司 |
提高细胞产生单克隆的能力的方法
|
|
CN112851826B
(zh)
*
|
2021-02-10 |
2023-08-11 |
上海煦顼技术有限公司 |
Upk2嵌合抗原受体及其尿道癌的治疗
|
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
|
US20220323500A1
(en)
|
2021-04-09 |
2022-10-13 |
Achilles Therapeutics Uk Limited |
Cancer immunotherapy
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
KR20240023426A
(ko)
|
2021-06-22 |
2024-02-21 |
아킬레스 테라퓨틱스 유케이 리미티드 |
항원-특이적 t 세포를 생산하는 방법
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN117355531A
(zh)
|
2021-06-23 |
2024-01-05 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
EP4398917A4
(en)
*
|
2021-09-09 |
2025-01-22 |
Mayo Foundation for Medical Education and Research |
CANCER TREATMENT
|
|
WO2023039548A1
(en)
*
|
2021-09-10 |
2023-03-16 |
Fred Hutchinson Cancer Center |
Kinase inhibitors for the treatment of prostate cancer
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
WO2023102712A1
(zh)
*
|
2021-12-07 |
2023-06-15 |
深圳市先康达生命科学有限公司 |
一种基因生物制剂及其制备方法和应用
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023214325A1
(en)
*
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
US20240091351A1
(en)
|
2022-09-21 |
2024-03-21 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
KR102886457B1
(ko)
*
|
2022-10-14 |
2025-11-18 |
강원대학교산학협력단 |
mTOR 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도
|
|
JP2026519263A
(ja)
|
2022-10-26 |
2026-06-15 |
ノバルティス アーゲー |
レンチウイルス製剤
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025084881A1
(ko)
*
|
2023-10-20 |
2025-04-24 |
주식회사 이온셀 |
Ct83 항원에 결합하는 car-t 세포 및 이의 용도
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025255093A1
(en)
*
|
2024-06-03 |
2025-12-11 |
Artax Biopharma Inc. |
Combination of a car-t therapy and a chromene derivative tcr inhibitor
|
|
WO2025255291A1
(en)
*
|
2024-06-07 |
2025-12-11 |
Memorial Sloan-Kettering Cancer Center |
Chimeric antigen receptors targeting mesothelin and use thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|